Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Omaha, Nebraska

Phase 1 cancer trials in Omaha, NE

38 Phase 1 cancer studies are recruiting participants at sites in Omaha as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Omaha at a glance

Breast cancer studies recruiting in Omaha

Basic details from each study's public record (the 30 most recently updated of 38). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

    • Phase 1/2
    • All ages
    • All sexes
    Sponsor
    RayzeBio, Inc.
    Registry record
    NCT06590857 · updated
  2. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Nebraska Cancer Specialists - Midwest Cancer Center - Legacy
    Registry record
    NCT03424005 · updated
  3. Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Novartis Pharmaceuticals
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT07660055 · updated
  4. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Terremoto Biosciences Inc.
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT07109726 · updated
  5. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Accent Therapeutics
    Study site
    University of Nebraska Medical Center
    Registry record
    NCT06799065 · updated
  6. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Radiopharm Theranostics, Ltd
    Study sites
    Nebraska Cancer Specialists · XCancer
    Registry record
    NCT07189871 · updated
  7. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399
    Registry record
    NCT05005403 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Omaha, NE on ClinicalTrials.gov.

Lung cancer studies recruiting in Omaha

  1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT07277413 · updated
  2. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Registry record
    NCT03460977 · updated
  3. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT04198766 · updated
  4. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tango Therapeutics, Inc.
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT06922591 · updated
  5. Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Molecular Partners AG
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT07278479 · updated
  6. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #2
    Registry record
    NCT05176483 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Omaha, NE on ClinicalTrials.gov.

Prostate cancer studies recruiting in Omaha

  1. RYZ711 Diagnostic Platform Study

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    RayzeBio, Inc.
    Registry record
    NCT07862582 · updated
  2. Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Urology Cancer Center, PC
    Registry record
    NCT06800313 · updated
  3. A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Aktis Oncology, Inc.
    Study site
    XCancer
    Registry record
    NCT07581184 · updated
  4. A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06879041 · updated
  5. Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

    • Phase 1/2
    • Ages 18 to 99
    • Male participants
    Sponsor
    AstraZeneca
    Registry record
    NCT07590934 · updated
  6. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Pathos AI, Inc.
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT06785636 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Omaha, NE on ClinicalTrials.gov.

Melanoma studies recruiting in Omaha

  1. MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT05655312 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Omaha, NE on ClinicalTrials.gov.

Lymphoma studies recruiting in Omaha

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study sites
    Children's Hospital and Medical Center of Omaha · University of Nebraska Medical Center
    Registry record
    NCT04726241 · updated
  2. A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Umoja Biopharma
    Study site
    University of Nebraska Medical Center
    Registry record
    NCT06528301 · updated
  3. A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    The University of Nebraska Medical Center
    Registry record
    NCT07195916 · updated
  4. CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Curis, Inc.
    Study site
    Fred and Pamela Buffett Cancer Center
    Registry record
    NCT03328078 · updated
  5. Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

    • Phase 1/2
    • Ages 16 to 75
    • All sexes
    Sponsor
    Leland Metheny
    Study site
    University of Nebraska Medical Center
    Registry record
    NCT03104491 · updated
  6. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    University of Nebraska Medical Center
    Registry record
    NCT05826535 · updated
  7. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    CellCentric Ltd.
    Study sites
    Nebraska Cancer Specialists · University of Nebraska Medical Center
    Registry record
    NCT04068597 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Omaha, NE on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Omaha

  1. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT06710756 · updated
  2. Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection

    • Phase 1
    • Ages 19 and older
    • All sexes
    Sponsor
    University of Nebraska
    Study site
    University of Nebraska Medical Center
    Registry record
    NCT06320990 · updated
  3. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study sites
    Nebraska Cancer Specialists · University of Nebraska Medical Center
    Registry record
    NCT06445062 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Omaha, NE on ClinicalTrials.gov.

Ask about studies near Omaha

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call